Should I buy or sell Prime Medicine stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares. View PRME analyst ratings or view top-rated stocks .

What is Prime Medicine's stock price target for 2024?

5 Wall Street research analysts have issued 12-month price targets for Prime Medicine's shares. Their PRME share price targets range from $19.00 to $26.00. On average, they predict the company's stock price to reach $21.60 in the next year. This suggests a possible upside of 175.2% from the stock's current price. View analysts price targets for PRME or view top-rated stocks among Wall Street analysts .

How have PRME shares performed in 2023?

Prime Medicine's stock was trading at $14.20 at the start of the year. Since then, PRME shares have decreased by 44.7% and is now trading at $7.85. View the best growth stocks for 2023 here .

When is Prime Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our PRME earnings forecast .

How were Prime Medicine's earnings last quarter?

Prime Medicine, Inc. (NYSE:PRME) announced its earnings results on Friday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.10.

What ETFs hold Prime Medicine's stock?

ETFs with the largest weight of Prime Medicine (NYSE:PRME) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , TrueShares Technology, AI & Deep Learning ETF (LRNZ) , ARK Genomic Revolution ETF (ARKG) and AXS Green Alpha ETF (NXTE) . iShares Genomics Immunology and Healthcare ETF (IDNA) .

When did Prime Medicine IPO?

(PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share.

Who are Prime Medicine's major shareholders?

Prime Medicine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (4.03%), Sumitomo Mitsui Trust Holdings Inc. (3.74%), ARK Investment Management LLC (2.70%), Greenwich Wealth Management LLC (0.45%), Northern Trust Corp (0.34%) and Charles Schwab Investment Management Inc. (0.30%). View institutional ownership trends .

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Prime Medicine Stock Price, News & Analysis (NYSE:PRME)

$7.85

-0.22 (-2.73%)

(As of 12/5/2023 ET)

Compare

Today's Range: $7.81
▼
$8.15
50-Day Range: $5.59
▼
$10.25
52-Week Range: $5.54
▼
$21.48

Volume: 326,949 shs
Average Volume: 345,155 shs
Market Capitalization: $763.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.60

Prime Medicine MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 175.2% Upside
$21.60 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.96) to ($1.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

678th out of 948 stocks

Biological Products, Except Diagnostic Industry

102nd out of 148 stocks

3.4

Analyst's Opinion

Consensus Rating
Prime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.60, Prime Medicine has a forecasted upside of 175.2% from its current price of $7.85.
Amount of Analyst Coverage
Prime Medicine has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PRME.

0.0

Dividend Strength

Dividend Yield
Prime Medicine does not currently pay a dividend.
Dividend Growth
Prime Medicine does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRME.

2.4

News and Social Media Coverage

News Sentiment
Prime Medicine has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Prime Medicine this week, compared to 1 article on an average week.
Search Interest
3 people have searched for PRME on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prime Medicine insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.29% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.41% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Prime Medicine are expected to decrease in the coming year, from ($1.96) to ($1.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prime Medicine is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prime Medicine is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prime Medicine has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prime Medicine Stock (NYSE:PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

PRME Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRME Stock News Headlines

December 2, 2023 | americanbankingnews.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Brokerages

December 2, 2023 | americanbankingnews.com

Financial Survey: Prime Medicine (PRME) and Its Peers

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 8, 2023 | markets.businessinsider.com

Prime Medicine’s Promising Outlook: Buy Rating Justified by Preclinical Success, Potential Partnerships, and Healthy Financials

November 8, 2023 | forbes.com

Amazon Announces New Benefit For Prime Members: Primary Care Services For $9 Per Month

November 7, 2023 | benzinga.com

Prime Medicine Stock (NASDAQ:PRME), Analyst Ratings, Price Targets, Predictions

November 5, 2023 | msn.com

Prime Medicine files for $500M mixed shelf

November 4, 2023 | finanznachrichten.de

Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 3, 2023 | finance.yahoo.com

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

October 24, 2023 | finance.yahoo.com

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

October 15, 2023 | usatoday.com

What to know about Amazon Prime Big Deal Days: The October 2023 sale is here

October 10, 2023 | businessinsider.com

How to get an Amazon Prime free trial: First-time subscribers can try before they buy for 30 days

October 9, 2023 | nasdaq.com

BMO Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation

October 9, 2023 | markets.businessinsider.com

Analyst Ratings for Prime Medicine

October 9, 2023 | markets.businessinsider.com

Prime Medicine’s Prospective Growth Driven by Superior Gene Editing Technology and Potential Treatments for High Unmet-Need Indications

October 8, 2023 | msn.com

Early Prime Day deals on household items worth stocking up on

September 27, 2023 | seekingalpha.com

Prime Medicine: Not Yet Primed For Retail Investment

September 26, 2023 | investing.com

Prime Securities Ltd (PRME)

September 23, 2023 | businessinsider.com

Amazon Prime

September 23, 2023 | barrons.com

Prime Medicine Inc.

August 31, 2023 | finance.yahoo.com

Prime Medicine to Present at Upcoming Investor Conferences

August 20, 2023 | fool.com

Prime Medicine (NASDAQ: PRME)

August 10, 2023 | cnet.com

Make the Most of Your Prime Membership With These Hidden Prime Perks

August 8, 2023 | finanznachrichten.de

Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 1, 2023 | msn.com

Guggenheim Initiates Coverage of Prime Medicine (PRME) with Buy Recommendation

July 25, 2023 | finance.yahoo.com

2 Cathie Wood Stocks That Could Be Hidden Gems

See More Headlines

Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PRME
CUSIP: N/A
CIK: 1894562
Web: primemedicine.com
Phone: 617-564-0013
Fax: N/A
Employees: 175
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.60
High Stock Price Target: $26.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +167.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-121,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -67.28%
Return on Assets: -57.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.69
Quick Ratio: 4.69

Sales & Book Value

Annual Sales: $5.21 million
Price / Sales: 150.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.35 per share
Price / Book: 2.41

Miscellaneous

Outstanding Shares: 97,320,000
Free Float: 73,684,000
Market Cap: $785.37 million
Optionable: Optionable
Beta: 1.19

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Keith Michael Gottesdiener M.D. (Age 69)
Ph.D., President, CEO, Secretary & Director
Comp: $924.04k
Dr. Ann L. Lee Ph.D. (Age 61)
Chief Technical Officer
Comp: $947.28k
Mr. Richard Brudnick (Age 66)
Chief Business Officer
Comp: $680.8k
Dr. Andrew Anzalone M.D. (Age 36)
Ph.D., Co-Founder & Head of Prime Editing Platform
Dr. David R. Liu Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Ms. Carman Alenson CPA (Age 58)
M.B.A., Chief Accounting Officer & Interim CFO
Dr. Meredith Goldwasser (Age 51)
Senior VP and Head of Strategy & Corporate Operations
Dr. Jeremy S. Duffield M.D. (Age 55)
Ph.D., Chief Scientific Officer
Comp: $994.4k
Dr. Karen Brown J.D.
Ph.D., Senior Vice President of Intellectual Property & Legal Affairs
Ms. Niamh Alix
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRME Stock Analysis - Frequently Asked Questions

Should I buy or sell Prime Medicine stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares.
View PRME analyst ratings or view top-rated stocks.
What is Prime Medicine's stock price target for 2024?: 5 Wall Street research analysts have issued 12-month price targets for Prime Medicine's shares. Their PRME share price targets range from $19.00 to $26.00. On average, they predict the company's stock price to reach $21.60 in the next year. This suggests a possible upside of 175.2% from the stock's current price.
View analysts price targets for PRME or view top-rated stocks among Wall Street analysts.
How have PRME shares performed in 2023?: Prime Medicine's stock was trading at $14.20 at the start of the year. Since then, PRME shares have decreased by 44.7% and is now trading at $7.85.
View the best growth stocks for 2023 here.
When is Prime Medicine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our PRME earnings forecast.
How were Prime Medicine's earnings last quarter?: Prime Medicine, Inc. (NYSE:PRME) announced its earnings results on Friday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.10.

What ETFs hold Prime Medicine's stock?: ETFs with the largest weight of Prime Medicine (NYSE:PRME) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), TrueShares Technology, AI & Deep Learning ETF (LRNZ), ARK Genomic Revolution ETF (ARKG) and AXS Green Alpha ETF (NXTE).iShares Genomics Immunology and Healthcare ETF (IDNA).
When did Prime Medicine IPO?: (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share.
Who are Prime Medicine's major shareholders?: Prime Medicine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (4.03%), Sumitomo Mitsui Trust Holdings Inc. (3.74%), ARK Investment Management LLC (2.70%), Greenwich Wealth Management LLC (0.45%), Northern Trust Corp (0.34%) and Charles Schwab Investment Management Inc. (0.30%).
View institutional ownership trends.
How do I buy shares of Prime Medicine?: Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:PRME) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prime Medicine Stock Price, News & Analysis (NYSE:PRME)

Prime Medicine MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Prime Medicine Stock (NYSE:PRME)

PRME Stock Price History

PRME Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRME Stock Analysis - Frequently Asked Questions

Overall MarketRank^™